Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) currently has a daily average trading volume of 1.02M but it saw 1079449 shares traded in last market. With a market cap of 35.15M USD, the company’s current market price of $0.51 came falling about -4.90 while comparing to the previous closing price of $0.54. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.37 and as low as $0.13.
Taking a look at 20-day trading activity of Brainstorm Cell Therapeutics, Inc. (BCLI) gives us an average price of $0.6105, while its current price level is -84.75% below from 52-week high level whereas it is 283.81% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.4571 while that of 200 days or SMA-200 reads an average of $0.6880. A closer look into the stock’s movement over the week reveals that its volatility is standing at 17.49% during that period while stretching the period over a month that increases to 22.22%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 47.15 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Maxim Group which upgraded the stock as “Buy” in its note to investors issued on February 04, 2021, recommending a price target of $12 for it. Maxim Group issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $5 and $6.
Over the week, BCLI’s stock price is moving -10.88% down while it is 44.59% when we observe its performance for the past one month. Year-to-date it is 88.39% up and over the past year, the stock is showing a downside performance of -80.30%.
Currently, Brainstorm Cell Therapeutics, Inc.’s total number of outstanding shares is 60.49M. Company’s return on equity (ROE) at -1121.89%. Stock’s beta reads 0.31. Its return on asset (ROA) is -271.62% on average.
